BLTE News and Press, Belite Bio Inc From 05/30/23

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have si...

2023-05-30 16:07:45 ET Biopharmaceutical drug development company Belite Bio ( NASDAQ: BLTE ) said on Tuesday that it has commenced an underwritten public offering of American Depositary Shares. Each of the ADS represents one share and warrants to purchase shares. The comp...

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have si...

2023-05-22 17:47:48 ET Belite Bio ( NASDAQ: BLTE ) has filed for a $300M mixed shelf securities offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The company intends to use the proceeds for clinical trials and further cli...

2023-05-14 04:42:06 ET Belite Bio, Inc (BLTE) Q1 2023 Earnings Conference Call May 11, 2023 08:00 AM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conf...

2023-05-11 12:15:12 ET Belite Bio press release ( NASDAQ: BLTE ): Q1 GAAP EPS of -$0.10. As of March 31, 2023, the Company had $37.8 million in cash. For further details see: Belite Bio GAAP EPS of -$0.10

In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjects A continued trend of slowing expansion of autofluoresce...

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a li...

The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye dise...

Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time point A continued trend of slowing expansion of autofluorescence was observed The growth rate of incident atrophic retinal lesions was reduced compared t...